SCHEMBL4718059

SCHEMBL4718059

CC(C)(C)OC(=O)N(CCCO)Cc1ccccc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.50
EGFR P00533 2/20 0.40
CA14 Q9ULX7 1/20 0.39
TSHR P16473 2/20 0.39
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
RIPK1 Q13546 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
NFKB1 P19838 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
CHRM2 P08172 2/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29555802 0.90 EGFR (0.50) SSTR4EGFRCA14TSHRCTSS
SCHEMBL4715109 0.85 SSTR4 (0.52) SSTR4CA14RIPK1HSD17B10HDAC1
SCHEMBL13168302 0.84 SSTR4 (0.45) SSTR4TSHRCTSSCTSKRIPK1
SCHEMBL13166749 0.84 SSTR4 (0.45) SSTR4EGFRTSHRCTSSCTSK
SCHEMBL4719084 0.84 SSTR4 (0.46) SSTR4CA14TSHRCYP1A2CYP2C19
SCHEMBL1848202 0.82 HDAC1 (0.52) SSTR4CA14CTSSHDAC3HDAC1
SCHEMBL4718013 0.81 SSTR4 (0.43) SSTR4CA14LMNAHTT
SCHEMBL2979243 0.81 SSTR4 (0.55) SSTR4EGFRCA14CTSSCTSK
SCHEMBL7385502 0.81 SSTR4 (0.47) SSTR4CA14RIPK1HSD17B10HDAC1
SCHEMBL4719978 0.79 GPR52 (0.41) SSTR4EGFRTSHRCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed
EP-1216230-A2 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS Amgen Inc. (US) 2002-06-26 EP disclosed
WO-2001023357-A2 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC. (US) 2001-04-05 WO disclosed